Oleoylethanolamide, the gut's own fat-derived fullness signal, is sold as a dietary supplement for appetite and blood sugar. Small, short studies, mostly in obesity or early blood sugar problems, most consistently show modestly lower fasting blood sugar; weight loss appears small. Only worm and mouse studies address longevity. Side effects were mild over about four months; longer use is unknown. A plausible, low-risk add-on of uncertain benefit size and duration. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 70–99 mg/dL | Expected to change; safety check with glucose-lowering drugs |
| HbA1c | 4.0–5.6% | Expected to change (unconfirmed in pooled trials) |
| Fasting insulin / HOMA-IR | Insulin about 2.6–24.9 µIU/mL; HOMA-IR: track change from own baseline | Expected to change |
| Triglycerides | Below 150 mg/dL | Expected to change |
| hs-CRP | Track change from own baseline | Expected to change (inconsistent in trials) |
| ALT and AST | ALT about 7–56 U/L; AST about 10–40 U/L | Safety check; also expected to fall in fatty liver |
| Creatinine | About 0.6–1.3 mg/dL | Safety check (theoretical fibrate-like effect) |
| Body weight and waist circumference | No unwanted weight loss in lean users | Baseline reference point; guards against excess appetite loss |
Cadence: Baseline panel before starting; repeat at 8–12 weeks, then every 6 months if use continues. With glucose-lowering drugs, home glucose checks several times weekly during the first 2–4 weeks.